The future of drug development? Seeking evidence of activity of novel drugs in small groups of patients

Journal of Clinical Oncology

Volumn 31, Issue 18, 2013, Pages 2246-2248

  Sleijfer, Stefan ^a   Ballman, Karla ^b   Verweij, Jaap ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEDIRANIB; GROWTH HORMONE; HYBRID PROTEIN; IMATINIB; SUNITINIB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TFE2; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VISMODEGIB; QUINAZOLINE DERIVATIVE;

ALVEOLAR SOFT PART SARCOMA; ANTINEOPLASTIC ACTIVITY; BASAL CELL CARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL PRACTICE; DECISION MAKING; DERMATOFIBROSARCOMA PROTUBERANS; DISEASE COURSE; DRUG DEVELOPMENT; DRUG DOSE REDUCTION; EDITORIAL; EQUIPOISE; HAZARD RATIO; HISTOLOGY; HUMAN; INCIDENCE; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADICAL RESECTION; SOFT TISSUE SARCOMA; STOMACH CANCER; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME; DRUG EFFECT; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MALE; NOTE;

FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; QUINAZOLINES; SARCOMA, ALVEOLAR SOFT PART;

EID: 84883007148     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.48.7645     Document Type: Editorial

References (14)

1. Sleijfer S, Ouali M, van Glabbeke M, et al: Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer 46:72-83, 2010
2. Verweij J, Casali PG, Zalcberg J, et al: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 364:1127-1134, 2004
3. Rutkowski P, Van Glabbeke M, Rankin CJ, et al: Imatinib mesylate in advanced dermatofibrosarcoma protuberans: Pooled analysis of two phase II clinical trials. J Clin Oncol 28:1772-1779, 2010
4. Verweij J, van Oosterom A, Blay JY, et al: Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39:2006-2011, 2003
5. Pennacchioli E, Fiore M, Collini P, et al: Alveolar soft part sarcoma: Clinical presentation, treatment, and outcome in a series of 33 patients at a single institution. Ann Surg Oncol 17:3229-3233, 2010
6. Portera CA Jr, Ho V, Patel SR, et al: Alveolar soft part sarcoma: Clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer 91:585-591, 2001
7. Lazar AJ, Das P, Tuvin D, et al: Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin Cancer Res 13:7314-7321, 2007
8. Kummar S, Allen D, Monks A, et al: Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol 31:2296-2302, 2013
9. Stacchiotti S, Negri T, Zaffaroni N, et al: Sunitinib in advanced alveolar soft part sarcoma: Evidence of a direct antitumor effect. Ann Oncol 22:1682-1690, 2011
10. Gardner K, Judson I, Leahy M, et al: Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma. J Clin Oncol 28:541s, 2009 (suppl; abstr 10523)
11. Sekulic A, Migden MR, Oro AE, et al: Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366:2171-2179, 2012
12. US Food and Drug Administration: Vismodegib. http://www.fda.gov/Drugs/ InformationOnDrugs/ApprovedDrugs/ucm289571.htm
13. Zia MI, Siu LL, Pond GR, et al: Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol 23:6982-6991, 2005
14. Wagner AJ, Goldberg JM, Dubois SG, et al: Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factorassociated tumors: Results of a multicenter phase 2 trial. Cancer 118:5894-5902, 2012